North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

Published:2010-02 Issue:2 Volume:21 Page:269-274
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Perez E.A.,Hillman D.W.,Dentchev T.,Le-Lindqwister N.A.,Geeraerts L.H.,Fitch T.R.,Liu H.,Graham D.L.,Kahanic S.P.,Gross H.M.,Patel T.A.,Palmieri F.M.,Dueck A.C.

Funder

National Institutes of Health

Breast Cancer Research Foundation

Roche (XEL450); Genentech

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/2/269/932825/mdp512.pdf

Reference27 articles.

1. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?;Cardoso;Ann Oncol,2002

2. Cancer statistics 2009;Jemal;J Clin Oncol,2009

3. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer;Piccart-Gebhart;J Clin Oncol,2008

4. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results;O'Shaughnessy;J Clin Oncol,2002

5. First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy;Verma;Oncologist,2007

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiogenesis Inhibition in Breast Cancer;Breast Disease;2019

2. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis;Cancer;2018-10-14

3. Bevacizumab Combined with Chemotherapy in Children Affected by Hepatocellular Carcinoma: a Single-center Experience;Anticancer Research;2017-03-17

4. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study;Cancer;2016-07-14

5. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial;European Journal of Cancer;2014-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3